Comparative Pharmacology
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE 0 2 IN DEXTROSE 5 versus XYLOCAINE 1 5 W DEXTROSE 7 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE 0 2 IN DEXTROSE 5 versus XYLOCAINE 1 5 W DEXTROSE 7 5.
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% vs XYLOCAINE 1.5% W/ DEXTROSE 7.5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is a local anesthetic that stabilizes neuronal membranes by inhibiting sodium ion influx, thereby blocking initiation and conduction of nerve impulses.
Lidocaine is an amide-type local anesthetic that blocks sodium channels, thereby inhibiting the propagation of action potentials in peripheral nerves, leading to local anesthesia.
1-1.5 mg/kg IV bolus over 2-3 minutes, followed by continuous IV infusion of 1-4 mg/min for ventricular arrhythmias; maximum 3 mg/kg (or 200-300 mg) over 1 hour.
Spinal anesthesia: 1.5-2 mL (22.5-30 mg lidocaine) for lower extremity or perineal procedures; 2-3 mL (30-45 mg) for lower abdominal or urological procedures. Administered via lumbar puncture.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours (adults); prolonged in heart failure (up to 4-6 hours) or hepatic impairment (up to 5-7 hours).
Terminal elimination half-life: 1.5–2 hours in adults with normal hepatic function; may be prolonged to 3–5 hours in patients with hepatic impairment or congestive heart failure.
Renal: ~90% as metabolites and <10% unchanged. Biliary/fecal: minor (<1%).
Renal excretion of metabolites (predominantly 4-hydroxy-2,6-xylidine and conjugates) accounts for >80% of elimination; less than 10% eliminated unchanged in urine. Biliary/fecal excretion of metabolites contributes <10%.
Category A/B
Category C
Local Anesthetic / Antiarrhythmic (Class Ib)
Local Anesthetic